Daily Intelligence Brief
80% of Depo-Provera Claimants May Be Eligible for Settlement
On July 28, 2026, Depo-Provera Litigation (3140) received Case Management Order No. 12, separating confidential settlement administration from claims that will remain on the litigation track. The order estimates that about 80% of MDL plaintiffs qualify for the settlement program, with registration expected to close in November and payments anticipated in the first quarter of 2027. It also establishes a no-fee administrative docket while preserving proceedings for opt-out and ineligible claims. Yeager, Davis and Ponder will serve as replacement pilot cases, putting limitations issues first while leaving the Rule 702 hearing on general causation set for September 18.
Drug, Platform and Consumer Claims Define the Docket
Pharmaceutical, platform and consumer-product dockets drove the day’s concentrated intake, led by Depo-Provera Litigation (3140), where Murphy Law Firm filed six and Anapol Weiss five of 18 new cases. Social Media Adolescent Addiction Personal Injury Products Liability Litigation (3047) added 16 matters, with Keller Postman LLC filing seven and Weitz & Luxenberg PC three, while Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (3060) logged 15, including nine from Singleton Schreiber LLP and two from Johnson Law Group. Uber Technologies, Inc., Passenger Sexual Assault Litigation (3084) drew 14 cases evenly divided between Cutter Law PC and Phillips & Associates Law Firm PC, and Aqueous Film-Forming Foams Personal Injury Products Liability Litigation (2873) added nine, led by Environmental Litigation Group PC’s six and Clancy Fleishman LLP’s two. See the full filing feed and firm-level breakdowns here.
Dupixent Lymphoma Study Adds Comparative Evidence Record
On July 28, 2026, a retrospective cohort study comparing lymphoma risk among asthma patients treated with dupilumab and other biologics supplied current comparative evidence for Dupixent CTCL (3180). The publication places a new comparative record before counsel assessing alleged lymphoma and cutaneous T-cell lymphoma risk. It does not resolve product liability or establish causation for any individual claimant. Its immediate litigation value lies in sharpening scrutiny of the expert proof needed to distinguish a product-specific risk from competing clinical explanations.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
